The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials

COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials

March 25, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus.

You Might Also Like
  • Second Indian Firm Under Fire for Shoddy Clinical Drug Trials
  • Clinical Trials Ongoing for Brodalumab
  • Mitigate Risk and Increase Success of Lupus Clinical Trials

Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in the face of the pandemic that has killed over 16,000 people worldwide, after several small biotech companies said last week that they would be pulling back on drug studies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The moves are not related to clinical trials testing drugs or vaccines that could be used to treat or prevent COVID-19, the respiratory illness caused by the virus.

The U.S. Food and Drug Administration last week urged switching to virtual patient visits instead of in-person monitoring when conducting clinical studies as it anticipated the outbreak would disrupt them.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pfizer Inc, Merck & Co, AbbVie Inc, and Johnson & Johnson were not immediately available for comment on their trials policies.

Delaying clinical trials could hurt future revenue for pharmaceutical companies as it lengthens the time it takes for drugs to receive approval and reach the market. It could also hurt patients by limiting their access to experimental treatments being studied.

Lilly said the move would delay the timeline for ongoing late-stage studies of its experimental gastrointestinal disease treatment mirikizumab.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Indianapolis-based drugmaker said there will not be any delay in other ongoing late-stage trials.

It added that it would analyze ongoing trials on a study-by-study basis, as discontinuing them would disrupt the treatment course for patients. But it plans to continue most trials where patients are already enrolled.

Lilly said it does not anticipate any change to its full-year financial forecast as a result of the coronavirus outbreak.

Bristol posted a message to clinical trial investigators on its website on Friday, saying it will put off beginning new clinical trials for at least three weeks because of the impact of the rapidly spreading coronavirus pandemic.

The New York-based drugmaker said it will not initiate any new sites for clinical trials until April 13, noting that the timeframe of the halt could extend further.

It also said studies involving healthy volunteers should be put on hold if they are at a natural break point until at least April 13.

Bristol did not say how many trials or which drugs in development might be affected.

Financial Cost to Hospitals
Conducting clinical trials is a good source of revenue for non-profit and academic hospitals, but are not as significant for for-profit hospital companies, Jefferies Analyst Brian Tanquilut said.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: clinical trial, clinical trials, coronavirus, COVID-19, drugmakers, Research

You Might Also Like:
  • Second Indian Firm Under Fire for Shoddy Clinical Drug Trials
  • Clinical Trials Ongoing for Brodalumab
  • Mitigate Risk and Increase Success of Lupus Clinical Trials
  • Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.